EHMT2 and medulloblastoma: We have previously reported that higher G9a/Ehmt2 transcription may predict poor prognosis with shorter overall survival (OS) in patients with the Sonic Hedgehog (SHH) molecular subgroup of medulloblastoma, which is the main type of pediatric malignant brain tumor, and that inhibiting G9a activity can impair medulloblastoma cell viability [24].